Attending Difficult to treat RA…looking forward to learning new things about this. #Gowithus #ACR22 @IFAiArthritis https://t.co/ChET0ckm0X

@erasmusmcintl @RheumNow Data here from @earlyarthritis (CATCH Canada cohort), similar results. It's not just pain differences - but that's real too. It's lots of things, but whatever the case we ignore sex and gender's impact in RA at our peril. ABST0532 #ACR22 @Janetbirdope @TheLancetRheum @RheumNow https://t.co/27uQmNAlPF

How long do we hold meds for live-attenuated #Vaccines? ACR 2022 vax guidelines: 💉Pre-vax: 💊csDMARDs - hold time 4 wks 💊bDMARDs -hold time of one dosing interval 💉Post-vax: hold DMARDs for 4 wks #ACR22 @rheumnow @rheumarhyme @doktora_ging https://t.co/MGc422EtIC

#ACR22 Abs 0408 @philipcrobinson et al, nr-axSpA pts achieving long-term clinical outcomes w/ CZP tx after 1 yr were generally sustained over 3 yrs across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups; ASDAS-MI numerically highest in MRI+/CRP+. @RheumNow https://t.co/cjpp2qCN4O https://t.co/G2YjF6ubUf

Potential disconnect: Objective Inflammatory Response, OIR (MRI/CRP levels) vs Clinical Response,CR (BASDAI/ASDAS). Post hoc analysis AxSpA on Certolizumab. Majority of patients >50% improved OIR, only minority improved CR. Rudwaleit etal https://t.co/WdkmkCWClO #ACR22 @RheumNow https://t.co/qlNUFhnuJQ

I've always presumed biopsy-neg GCA just hit skip lesions sections What does RNA-Seq of temporal artery bx tell us? positive bx similar to skip lesions bx neg GCA very different Sometimes it's not just the sampling sometimes it's something different... ABST0486 #ACR22 @RheumNow https://t.co/QITgkZ21sy

Bimekizumab (IL-17A and IL-17F inhibitor) use in non-radiographic AxSpA resulted in rapid improvement of ASAS40 along with reduction in SPARCC MRI SI joint inflammation #Abs0544 @RheumNow #ACR22 https://t.co/pOCg0idGsR

2022 ACR guide for #vaccinations in RMD pts: 💉Influenza:⬆️dose or adjuvant (CR) >=65 & >18<65 on immunosuppressives 💉Pneumococcal: SR for <65 yrs, on immunosuppressives 💉Rec VZV: SR for >18y on immunosupressives 💉HPV: CR for >26y & <45y on meds & no prev vax #ACR22 @rheumnow https://t.co/2DlIqNUBct

What do you look for on temporal artery examination in GCA assessment? tenderness: minimally useful reduced/absent pulse or thickening: quite good if there, nearly as good as halo Good examination is powerful, if you're doing it right! ABST0483 Salvarani group #ACR22 @RheumNow https://t.co/B3qvSW68at

Abs 0406 demonstrates stronger relationship between disease activity (using BASFI and BASDAI) and quality of life in men w/ axSpA than women. IMO, it also demonstrates need for better assessment tools for women! #ACR22 @RheumNow https://t.co/B44ZixyeAJ https://t.co/lMzpsGcsFM

Abs0399 ASAS recs for requesting/reporting imaging in suspected AxSpA pts key takeaway: communication! Rheum provides pertinent hx (trauma, childbirth, pain location, duration, etc), DDx Rads summarize hx & give pertinent +/- exam findings #ACR22 @RheumNow https://t.co/Ucr8B5xfGA https://t.co/F6g15dQhj1

2022 ASAS-EULAR Recommendations of AxSpA management 1) NSAIDs still first line 2) Analgesics/opioids contraindicated 3) TNFi, IL-17i first line bDMARDs, followed by JAKinibs 4) Tapering but not discontinuation of bDMARDs in sustained remission Abs#0542 @RheumNow #ACR22 https://t.co/ffaN2fMc3v